Literature DB >> 17215650

Aldosterone and the vasculature: mechanisms mediating resistant hypertension.

Daniel A Duprez1.   

Abstract

The renin-angiotensin-aldosterone system appears to be one of the key factors in the development of hypertensive vascular disease. Identification of mineralocorticoid receptors in the heart, vasculature, and brain has raised speculation that aldosterone may directly mediate its detrimental effects in these target organs independent of angiotensin II. Aldosterone increases vascular tone due to endothelial dysfunction and enhances the pressor response to catecholamines and up-regulation of angiotensin II receptors. It induces electrolyte transport over the vascular smooth cell membrane and plays a crucial role in vascular remodeling of small and large arteries. Moreover, aldosterone is involved in vascular injury and promotes collagen synthesis, which leads to increased arterial stiffness and elevation of blood pressure. Aldosterone has also been shown to exert a number of effects in the central nervous system. Several human studies have shown that aldosterone is related to baroreflex resetting. Thus, in cases of severe hypertension, there would be fewer compensatory mechanisms to offset blood pressure elevation and ensuing vascular damage. Endothelial and vascular smooth muscle cells have the potential to synthesize aldosterone, and tissue aldosterone could play a more important role in resistant hypertension and target organ damage than circulating aldosterone. Understanding aldosterone synthase polymorphism may provide insight into blood pressure patterns and their consequences. Understanding the vascular mechanisms of aldosterone in resistant hypertension may explain why selective aldosterone receptor blockers might have beneficial effects in resistant hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17215650      PMCID: PMC8110152          DOI: 10.1111/j.1524-6175.2007.06367.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  40 in total

1.  Aldosterone--villain or bystander?

Authors:  Robert G Dluhy; Gordon H Williams
Journal:  N Engl J Med       Date:  2004-07-01       Impact factor: 91.245

2.  Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension.

Authors:  Mari K Nishizaka; Monique Pratt-Ubunama; Mohammad A Zaman; Stacey Cofield; David A Calhoun
Journal:  Am J Hypertens       Date:  2005-06       Impact factor: 2.689

3.  Aldosterone blunts human baroreflex sensitivity by a nongenomic mechanism.

Authors:  B M W Schmidt; K Horisberger; M Feuring; A Schultz; M Wehling
Journal:  Exp Clin Endocrinol Diabetes       Date:  2005-05       Impact factor: 2.949

4.  Aldosterone induces a vascular inflammatory phenotype in the rat heart.

Authors:  Ricardo Rocha; Amy E Rudolph; Gregory E Frierdich; Denise A Nachowiak; Beverly K Kekec; Eric A G Blomme; Ellen G McMahon; John A Delyani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

5.  Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease.

Authors:  P Clarkson; D S Celermajer; A J Powe; A E Donald; R M Henry; J E Deanfield
Journal:  Circulation       Date:  1997-11-18       Impact factor: 29.690

6.  Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor.

Authors:  M Lombès; M E Oblin; J M Gasc; E E Baulieu; N Farman; J P Bonvalet
Journal:  Circ Res       Date:  1992-09       Impact factor: 17.367

7.  Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.

Authors:  C G Brilla; K T Weber
Journal:  J Lab Clin Med       Date:  1992-12

8.  Rapid nongenomic effects of aldosterone on the renal vasculature in humans.

Authors:  Bernhard M W Schmidt; Ulla Sammer; Ingrid Fleischmann; Markus Schlaich; Christian Delles; Roland E Schmieder
Journal:  Hypertension       Date:  2006-03-06       Impact factor: 10.190

Review 9.  Importance of the blood pressure-heart rate relationship.

Authors:  B Folkow; D Ely
Journal:  Blood Press       Date:  1998-05       Impact factor: 2.835

10.  Vasodilation to acetylcholine in primary and secondary forms of human hypertension.

Authors:  S Taddei; A Virdis; P Mattei; A Salvetti
Journal:  Hypertension       Date:  1993-06       Impact factor: 10.190

View more
  14 in total

1.  Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study.

Authors:  Eduardo Pimenta; Richard D Gordon; Ashraf H Ahmed; Diane Cowley; Rodel Leano; Thomas H Marwick; Michael Stowasser
Journal:  J Clin Endocrinol Metab       Date:  2011-06-01       Impact factor: 5.958

Review 2.  Resistant Hypertension: Mechanisms and Treatment.

Authors:  Andrew Y Hwang; Eric Dietrich; Carl J Pepine; Steven M Smith
Journal:  Curr Hypertens Rep       Date:  2017-07       Impact factor: 5.369

3.  Differential aerobic exercise-induced changes in plasma aldosterone between African Americans and Caucasians.

Authors:  Jennifer M Jones; Thomas C Dowling; Jung-Jun Park; Dana A Phares; Joon-Young Park; Thomas O Obisesan; Michael D Brown
Journal:  Exp Physiol       Date:  2007-05-04       Impact factor: 2.969

4.  Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?

Authors:  Michael Gekle; Claudia Grossmann
Journal:  Pflugers Arch       Date:  2008-11-19       Impact factor: 3.657

Review 5.  Resistant hypertension.

Authors:  Sheldon W Tobe; Richard Lewanczuk
Journal:  Can J Cardiol       Date:  2009-05       Impact factor: 5.223

6.  Long-term BP control and vascular health in patients with hyperaldosteronism treated with low-dose, amiloride-based therapy.

Authors:  Joseph L Izzo; Michael Hong; Tanveer Hussain; Peter J Osmond
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-06-06       Impact factor: 3.738

7.  Maintenance of long-term blood pressure control and vascular health by low-dose amiloride-based therapy in hyperaldosteronism.

Authors:  Joseph L Izzo; Michael Hong; Tanveer Hussain; Peter J Osmond
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-07-26       Impact factor: 3.738

8.  Resistant hypertension workup and approach to treatment.

Authors:  Anastasios Makris; Maria Seferou; Dimitris P Papadopoulos
Journal:  Int J Hypertens       Date:  2010-12-26       Impact factor: 2.420

9.  Clinical approach in treatment of resistant hypertension.

Authors:  Jennifer Frank; David Sommerfeld
Journal:  Integr Blood Press Control       Date:  2009-07-30

10.  Aldosterone excess or escape: Treating resistant hypertension.

Authors:  Samira Ubaid-Girioli; Leoní Adriana de Souza; Juan Carlos Yugar-Toledo; Luiz Cláudio Martins; Sílvia Ferreira-Melo; Otávio Rizzi Coelho; Cristina Sierra; Antonio Coca; Eduardo Pimenta; Heitor Moreno
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-05       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.